The Department of the Army Medical Command awarded a $2,843,750 Project Grant to The Trustees of the University of Pennsylvania under the Military Medical Research and Development program (CFDA 12.420). The grant supports the Department of Defense Omics Consortium to Study the Origins of Ovarian Cancer (DOCSOOC) from August 15, 2022 to August 14, 2026. The Consortium will develop a pathology resource for pan-omic studies of tubal precursors to ovarian cancer. It will facilitate communication and...
This Cooperative Agreement award, valued at $19,975,214.00, was granted by the Uniformed Services University of the Health Sciences (USUHS) under the Uniformed Services University Medical Research Projects program (CFDA 12.750). The award will fund the "BREAST CANCER OF EXCELLENCE (BREAST-COE) CORE" and "BREAST CANCER OF EXCELLENCE (BREAST-COE)" projects over the period of May 1, 2025 to April 30, 2028. The primary awardee, The Henry M. Jackson Foundation for the...
This Project Grant award of $1,562,257.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research on targeting de novo pyrimidine synthesis to treat ovarian cancer. The primary awardee, The Ohio State University, will collaborate with the University of South Florida on this effort. Key research activities include designing experiments to investigate the role of pyrimidine synthesis in...
This $9.58 million cooperative agreement from the Defense Health Agency will fund research from Duke University on targeting breast cancer and modulating host immune responses. The award is part of the Military Medical Research and Development program and runs from September 2021 through September 2025. Duke University will lead efforts to identify organoids naturally harboring PTEN mutations or deletions in triple negative breast cancer to generate 3D models. Researchers will define immune...
The federal Project Grant award of $1,489,868.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports the "OVARIAN CANCER ACADEMY: ADVANCING OVARIAN CANCER RESEARCH THROUGH MENTORSHIP, NETWORKING, AND COLLABORATIONS" project. The award, effective from September 30, 2025 to September 29, 2029, will be executed by the Trustees of Indiana University, a prominent public research university system. The project aims to transform...
This federal Project Grant award for $1,305,270.00, titled "OVARIAN CANCER ACADEMY: ADVANCING OVARIAN CANCER RESEARCH THROUGH MENTORSHIP, NETWORKING, AND COLLABORATIONS", was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award will support advanced biomedical research focused on transforming healthcare for military service members and the public through the University of Pennsylvania's Clinical Practices. Key...
This federal Project Grant award in the amount of $1,439,093.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of New Mexico Health Sciences Center (UNM HSC). The grant will support advancing clinical research on ovarian cancer over a performance period from June 1, 2024 to May 31, 2028. As part of this award, UNM HSC will leverage its expertise in cancer research, genomics, and clinical trials to conduct...
This $11.7 million cooperative agreement from the Department of the Army Medical Command will fund research from August 1, 2022 to July 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Fred Hutchinson Cancer Center will work with sub-awardees the University of Washington and The Washington University to prevent lethal metastatic breast cancer. Specifically, the recipients will identify and eradicate clinically relevant disseminated tumor cells by recruiting...
This $472,498 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at The Ohio State University to target the UPP1-mediated pyrimidine salvage pathway to prevent ovarian cancer recurrence. The research aims to develop innovative approaches to disease prevention, diagnosis, and treatment for conditions relevant to military personnel and the broader public. This 2-year project,...
This $1,372,184 federal Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research on the use of gonadotropin-releasing hormone analogs to protect ovarian reserve in adolescents and young adults with cancer. The primary awardee, Fred Hutchinson Cancer Center, will oversee the overall study design, data analysis, and project administration. Sub-awards were made to The Cleveland Clinic Foundation to contribute...
This $8.58 million cooperative agreement from the Department of Defense's Uniformed Services University Medical Research Projects program (CFDA 12.750) supports the Gynecologic Cancer Center of Excellence (GYN-COE) Core from April 2021 through April 2023. The GYN-COE aims to identify molecular alterations in gynecologic cancers and develop novel strategies for prevention, early detection, and precision treatment through investigating carcinogenesis and drug resistance in pre-clinical and clinical biospecimens; developing and deploying clinical biomarkers and assays; improving clinical care through evaluation of novel therapeutics and clinical trials; collaborating on investigations of disparities, risk, and treatment; and utilizing military and civilian resources to advance applied proteogenomics and ensure readiness and improved outcomes.
The award supports a tissue and data acquisition network involving subawards to Duke University, the University of Virginia, the University of Oklahoma Health Sciences Center, Ohio State University, and Inova Fairfax Hospital to facilitate specimen and data collection to support future research studies through protocol participation and multidisciplinary collaboration. Principal investigators at the subaward institutions will oversee local execution of the tissue banking protocol and collaborative research initiatives.